While on long-term treatment with Abbvie’s experimental oral drug tavapadon, most people with early Parkinson’s disease did not need to start levodopa — the mainstay therapy for the progressive condition — and most individuals already taking levodopa didn’t need to increase their dose. That’s according to new results…

A new experimental oral therapy called VQ-101 successfully reached the brain and increased the activity of a key protective protein in people with Parkinson’s disease, according to early trial results. The Phase 1 study showed that the treatment, developed by Vanqua Bio,…

I was his niece, but Uncle Brandon meant much more to me. He felt like a second father. Back then, my dad worked nights as he tried to build his teaching career, so we didn’t see him much. To be honest, there was also an emotional distance. He grew up…

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel continues to show potential to control motor symptoms in people with Parkinson’s disease, with the benefits of a single dose sustained for up to three years in a small Phase 1 trial. These findings from the Phase 1 exPDite study (NCT04802733),…

People with Parkinson’s disease who switch from other levodopa/carbidopa formulations to Vyalev (foscarbidopa and foslevodopa) usually see uncontrolled movements stop within a few months of making the switch, according to a new analysis of data from two clinical trials. A team including scientists at AbbVie, the company…